Target regimen profiles for tuberculosis treatment.

Autor: Lienhardt C; French National Research Institute for Sustainable Development, Montpellier, France., Dooley KE; Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America (USA)., Nahid P; Institute for Global Health, University of California San Francisco, San Francisco, USA., Wells C; Bill & Melinda Gates Medical Research Institute, Boston, USA., Ryckman TS; Infectious Disease Division, School of Medicine, John Hopkins University, Baltimore, USA., Kendall EA; Infectious Disease Division, School of Medicine, John Hopkins University, Baltimore, USA., Davies G; Institute of Infection and Global Health, University of Liverpool, Liverpool, England., Brigden G; The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland., Churchyard G; Aurum Institute, Johannesburg, South Africa., Cirillo DM; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, Milan, Italy., Di Meco E; European Medicines Agency, Amsterdam, Kingdom of the Netherlands., Gopinath R; Division of Anti-Infectives, Food and Drug Administration, WashingtonDC, USA., Mitnick C; School of Medicine, Harvard Medical School, Boston, USA., Scott C; Unitaid, Geneva, Switzerland., Amanullah F; Indus Hospital, Karachi, Pakistan., Bansbach C; ChinaCat Enterprises, Gig Harbor, USA., Boeree M; University Medical Center, Radboud University, Amsterdam, Kingdom of the Netherlands., Campbell M; Clinton Health Access Initiative, Boston, USA., Conradie F; Wits Health Consortium, Johannesburg, South Africa., Crook A; MRC Clinical Trials Unit, University College of London, London, England., Daley CL; Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, USA., Dheda K; Centre for Lung Infection and Immunity, University of Cape Town, Cape Town, South Africa., Diacon A; TASK, Cape Town, South Africa., Gebhard A; KNCV, The Hague, Kingdom of the Netherlands., Hanna D; Global Health Division, Bill & Melinda Gates Foundation, Seattle, USA., Heinrich N; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU, Munich, Germany., Hesseling A; Desmond Tutu TB Centre, Stellenbosch University, Stellenbosch, South Africa., Holtzman D; Bill & Melinda Gates Medical Research Institute, Boston, USA., Jachym M; Centre Hospitalier de Bligny, Fontenay-lès-Briis, Paris, France., Kim P; French National Research Institute for Sustainable Development, Montpellier, France.; Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America (USA)., Lange C; French National Research Institute for Sustainable Development, Montpellier, France.; Institute for Global Health, University of California San Francisco, San Francisco, USA., McKenna L; French National Research Institute for Sustainable Development, Montpellier, France.; Bill & Melinda Gates Medical Research Institute, Boston, USA., Meintjes G; French National Research Institute for Sustainable Development, Montpellier, France.; Infectious Disease Division, School of Medicine, John Hopkins University, Baltimore, USA., Ndjeka N; French National Research Institute for Sustainable Development, Montpellier, France.; Institute of Infection and Global Health, University of Liverpool, Liverpool, England., Nhung NV; French National Research Institute for Sustainable Development, Montpellier, France.; The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland., Nyang'wa BT; French National Research Institute for Sustainable Development, Montpellier, France.; Aurum Institute, Johannesburg, South Africa., Paton NI; French National Research Institute for Sustainable Development, Montpellier, France.; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, Milan, Italy., Rao R; French National Research Institute for Sustainable Development, Montpellier, France.; European Medicines Agency, Amsterdam, Kingdom of the Netherlands., Rich M; French National Research Institute for Sustainable Development, Montpellier, France.; Division of Anti-Infectives, Food and Drug Administration, WashingtonDC, USA., Savic R; Institute for Global Health, University of California San Francisco, San Francisco, USA., Schoeman I; French National Research Institute for Sustainable Development, Montpellier, France.; School of Medicine, Harvard Medical School, Boston, USA., Makokotlela BS; French National Research Institute for Sustainable Development, Montpellier, France.; Unitaid, Geneva, Switzerland., Spigelman M; French National Research Institute for Sustainable Development, Montpellier, France.; Indus Hospital, Karachi, Pakistan., Sun E; French National Research Institute for Sustainable Development, Montpellier, France.; Indus Hospital, Karachi, Pakistan., Svensson E; University Medical Center, Radboud University, Amsterdam, Kingdom of the Netherlands., Tisile P; French National Research Institute for Sustainable Development, Montpellier, France.; School of Medicine, Harvard Medical School, Boston, USA., Varaine F; French National Research Institute for Sustainable Development, Montpellier, France.; ChinaCat Enterprises, Gig Harbor, USA., Vernon A; French National Research Institute for Sustainable Development, Montpellier, France.; University Medical Center, Radboud University, Amsterdam, Kingdom of the Netherlands., Diul MY; French National Research Institute for Sustainable Development, Montpellier, France.; Clinton Health Access Initiative, Boston, USA., Kasaeva T; French National Research Institute for Sustainable Development, Montpellier, France.; Wits Health Consortium, Johannesburg, South Africa., Zignol M; French National Research Institute for Sustainable Development, Montpellier, France.; Wits Health Consortium, Johannesburg, South Africa., Gegia M; French National Research Institute for Sustainable Development, Montpellier, France.; Wits Health Consortium, Johannesburg, South Africa., Mirzayev F; French National Research Institute for Sustainable Development, Montpellier, France.; Wits Health Consortium, Johannesburg, South Africa., Schumacher SG; French National Research Institute for Sustainable Development, Montpellier, France.; Wits Health Consortium, Johannesburg, South Africa.

Publikováno v: Bulletin of the World Health Organization [Bull World Health Organ] 2024 Aug 01; Vol. 102 (8), pp. 600-607. Date of Electronic Publication: 2024 May 28.

Multi-stakeholder consensus on a target product profile for an HIV cure

Autor: Deeks, S.G., SenGupta, D., Rooney, J.F., Bansbach, C., McCune, J.M., Sunnylands 2019 Working Group, Ndung'u, T., Ripin, D., Nsubuga, M., Dub��, K., Pottage, J., Sikazwe, I., Jiang, A., Johnston, R., Doehle, B., Nabel, G.J., Warren, M., Dybul, M., Lewin, S.R., Lamplough, R., Attoye, T.

Developing a cure for HIV is a global priority. Target product profiles are a tool commonly used throughout the drug development process to align interested parties around a clear set of goals or requirements for a potential product. Three distinct t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c80dfc9bbc772c3cfe8a068d375c8dcd

Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens.

Autor: Walter ND; Rocky Mountain Regional VA Medical Center, Aurora, CO, USA. nicholas.walter@cuanschutz.edu.; Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. nicholas.walter@cuanschutz.edu.; Consortium for Applied Microbial Metrics, Aurora, CO, USA. nicholas.walter@cuanschutz.edu., Born SEM; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Robertson GT; Consortium for Applied Microbial Metrics, Aurora, CO, USA.; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA., Reichlen M; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Dide-Agossou C; Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA., Ektnitphong VA; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA., Rossmassler K; Rocky Mountain Regional VA Medical Center, Aurora, CO, USA.; Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Ramey ME; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA., Bauman AA; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA., Ozols V; Rocky Mountain Regional VA Medical Center, Aurora, CO, USA.; Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Bearrows SC; Rocky Mountain Regional VA Medical Center, Aurora, CO, USA.; Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Schoolnik G; Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, CA, USA., Dolganov G; Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, CA, USA., Garcia B; Integrated Center for Genes, Environment, and Health, National Jewish Health, Denver, CO, USA.; Computational Bioscience Program, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Musisi E; Infectious Disease Research Collaboration, Kampala, Uganda.; Department of Biochemistry, Makerere University, Kampala, Uganda., Worodria W; Infectious Disease Research Collaboration, Kampala, Uganda., Huang L; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA.; Division of HIV, Infectious Diseases and Global Medicine, University of California San Francisco, San Francisco, CA, USA.; Zuckerberg San Francisco General Hospital, San Francisco, CA, USA., Davis JL; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.; Pulmonary, Critical Care, and Sleep Medicine Section, Yale School of Medicine, New Haven, CT, USA., Nguyen NV; Vietnam National TB Programme/UCSF Research Collaboration Unit, Hanoi, Vietnam., Nguyen HV; Vietnam National TB Programme/UCSF Research Collaboration Unit, Hanoi, Vietnam., Nguyen ATV; Vietnam National TB Programme/UCSF Research Collaboration Unit, Hanoi, Vietnam., Phan H; Vietnam National TB Programme/UCSF Research Collaboration Unit, Hanoi, Vietnam., Wilusz C; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA., Podell BK; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA., Sanoussi ND; Laboratoire de Référence des Mycobactéries, Cotonou, Benin., de Jong BC; Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium., Merle CS; London School of Hygiene and Tropical Medicine, London, UK.; UNICEF/UNDP/World Bank/WHO Special Programme on Research and Training in Tropical Disease, Geneva CH, Switzerland., Affolabi D; Laboratoire de Référence des Mycobactéries, Cotonou, Benin., McIlleron H; Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Garcia-Cremades M; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA., Maidji E; Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA., Eshun-Wilson F; Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA., Aguilar-Rodriguez B; Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA., Karthikeyan D; Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA., Mdluli K; Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA., Bansbach C; Bill and Melinda Gates Foundation, Seattle, WA, USA., Lenaerts AJ; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA., Savic RM; Consortium for Applied Microbial Metrics, Aurora, CO, USA.; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.; UCSF Center for Tuberculosis, University of California, San Francisco, CA, USA., Nahid P; Consortium for Applied Microbial Metrics, Aurora, CO, USA.; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA.; Zuckerberg San Francisco General Hospital, San Francisco, CA, USA.; Vietnam National TB Programme/UCSF Research Collaboration Unit, Hanoi, Vietnam.; UCSF Center for Tuberculosis, University of California, San Francisco, CA, USA., Vásquez JJ; Consortium for Applied Microbial Metrics, Aurora, CO, USA.; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA.; Zuckerberg San Francisco General Hospital, San Francisco, CA, USA.; Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA.; UCSF Center for Tuberculosis, University of California, San Francisco, CA, USA., Voskuil MI; Consortium for Applied Microbial Metrics, Aurora, CO, USA. martin.voskuil@cuanschutz.edu.; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. martin.voskuil@cuanschutz.edu.

Publikováno v: Nature communications [Nat Commun] 2021 May 18; Vol. 12 (1), pp. 2899. Date of Electronic Publication: 2021 May 18.

Multi-stakeholder consensus on a target product profile for an HIV cure.

Autor: Lewin SR; The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia; Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, VIC, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC, Australia. Electronic address: sharon.lewin@unimelb.edu.au., Attoye T; Department of Global Health, University of Washington, The Bill & Melinda Gates Foundation, Seattle, WA, USA., Bansbach C; Bill & Melinda Gates Foundation, Seattle, WA, USA., Doehle B; HIV Frontiers, Global Health Innovative Technology Solutions, The Bill & Melinda Gates Foundation, Seattle, WA, USA., Dubé K; University North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA., Dybul M; Center for Global Health Practice and Impact, Georgetown University, Washington, DC, USA., SenGupta D; Gilead Sciences, Foster City, CA, USA., Jiang A; McKinsey & Company Secondee at The Bill & Melinda Gates Foundation, Seattle, WA, USA., Johnston R; amfAR, The Foundation for AIDS Research, New York City, NY, USA., Lamplough R; International AIDS Society, Geneva, Switzerland., McCune JM; HIV Frontiers, Global Health Innovative Technology Solutions, The Bill & Melinda Gates Foundation, Seattle, WA, USA., Nabel GJ; Sanofi Global Research and Development, Cambridge, MA, USA., Ndung'u T; Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; Max Planck Institute for Infection Biology, Berlin, Germany; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA; Division of Infection and Immunity, University College London, London, UK., Pottage J; ViiV Healthcare, Brentford, UK., Ripin D; Clinton Health Access Initiative, Boston, MA, USA., Rooney JF; Gilead Sciences, Foster City, CA, USA., Sikazwe I; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia., Nsubuga M; Joint Adherent Brothers & Sisters against AIDS, Kampala, Uganda., Warren M; AVAC, New York, NY, USA., Deeks SG; University of California, San Francisco, CA, USA.

Publikováno v: The lancet. HIV [Lancet HIV] 2021 Jan; Vol. 8 (1), pp. e42-e50. Date of Electronic Publication: 2020 Nov 30.

Advances in HIV Gene Therapy.

Autor: Kitawi, Rose¹ (AUTHOR) rkitawi@kirby.unsw.edu.au, Ledger, Scott¹ (AUTHOR) akelleher@kirby.unsw.edu.au, Kelleher, Anthony D.^1,2,3 (AUTHOR), Ahlenstiel, Chantelle L.^1,3 (AUTHOR) cahlenstiel@kirby.unsw.edu.au

Publikováno v: International Journal of Molecular Sciences. Mar2024, Vol. 25 Issue 5, p2771. 28p.